Chimerix ((CMRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimerix is conducting a Phase I study titled ‘A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms.’ The study aims to evaluate the safety and tolerability of ONC206, a drug designed to treat recurrent CNS tumors, by determining the maximum-tolerated dose and identifying any dose-limiting toxicities.
ONC206, the drug under investigation, is an experimental anti-cancer small molecule targeting G protein-coupled receptors. It belongs to the imipridone class and is being tested for its effectiveness in treating central nervous system neoplasms.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. The study is open-label, meaning both researchers and participants know which treatment is being administered.
The study began on October 26, 2020, and is currently recruiting participants. The last update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The ongoing study could influence Chimerix’s stock performance, as positive results may boost investor confidence and market value. The competitive landscape includes other companies researching CNS treatments, which could affect market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.